These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 21326222)
1. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Arijs I; De Hertogh G; Machiels K; Van Steen K; Lemaire K; Schraenen A; Van Lommel L; Quintens R; Van Assche G; Vermeire S; Schuit F; Rutgeerts P Am J Gastroenterol; 2011 Apr; 106(4):748-61. PubMed ID: 21326222 [TBL] [Abstract][Full Text] [Related]
2. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. Banks C; Bateman A; Payne R; Johnson P; Sheron N J Pathol; 2003 Jan; 199(1):28-35. PubMed ID: 12474223 [TBL] [Abstract][Full Text] [Related]
3. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis. Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924 [TBL] [Abstract][Full Text] [Related]
4. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435 [TBL] [Abstract][Full Text] [Related]
5. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+CD45RBhigh T cells. Scheerens H; Hessel E; de Waal-Malefyt R; Leach MW; Rennick D Eur J Immunol; 2001 May; 31(5):1465-74. PubMed ID: 11465103 [TBL] [Abstract][Full Text] [Related]
6. Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases. Martinesi M; Treves C; Bonanomi AG; Milla M; Bagnoli S; Zuegel U; Steinmeyer A; Stio M Clin Immunol; 2010 Jul; 136(1):51-60. PubMed ID: 20399147 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of the fragile histidine triad (FHIT) gene in inflammatory bowel disease. Wierzbicki PM; Adrych K; Kartanowicz D; Wypych J; Stanislawowski M; Zwolinska-Wcislo M; Celinski K; Skrodzka D; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():57-62. PubMed ID: 20083852 [TBL] [Abstract][Full Text] [Related]
9. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. Klebl FH; Olsen JE; Jain S; Doe WF J Pathol; 2001 Dec; 195(5):609-15. PubMed ID: 11745698 [TBL] [Abstract][Full Text] [Related]
10. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068 [TBL] [Abstract][Full Text] [Related]
11. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment. Siddique I; Hasan F; Khan I Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066 [TBL] [Abstract][Full Text] [Related]
12. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Vetrano S; Borroni EM; Sarukhan A; Savino B; Bonecchi R; Correale C; Arena V; Fantini M; Roncalli M; Malesci A; Mantovani A; Locati M; Danese S Gut; 2010 Feb; 59(2):197-206. PubMed ID: 19846409 [TBL] [Abstract][Full Text] [Related]
13. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Puleston J; Cooper M; Murch S; Bid K; Makh S; Ashwood P; Bingham AH; Green H; Moss P; Dhillon A; Morris R; Strobel S; Gelinas R; Pounder RE; Platt A Aliment Pharmacol Ther; 2005 Jan; 21(2):109-20. PubMed ID: 15679760 [TBL] [Abstract][Full Text] [Related]
14. Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Brost S; Koschny R; Sykora J; Stremmel W; Lasitschka F; Walczak H; Ganten TM Pathol Res Pract; 2010 Jan; 206(1):43-50. PubMed ID: 19954896 [TBL] [Abstract][Full Text] [Related]
15. In-situ endothelial cell adhesion molecule expression in ulcerative colitis. E-selectin in-situ expression correlates with clinical, endoscopic and histological activity and outcome. Cellier C; Patey N; Fromont-Hankard G; Cervoni JP; Leborgne M; Chaussade S; Barbier JP; Brousse N Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1197-203. PubMed ID: 9471026 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569 [TBL] [Abstract][Full Text] [Related]